A
Allen C. Ho
Researcher at Wills Eye Institute
Publications - 53
Citations - 8086
Allen C. Ho is an academic researcher from Wills Eye Institute. The author has contributed to research in topics: Medicine & Visual acuity. The author has an hindex of 22, co-authored 25 publications receiving 6986 citations. Previous affiliations of Allen C. Ho include University of Pennsylvania & Thomas Jefferson University.
Papers
More filters
Journal ArticleDOI
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S. Heier,David M. Brown,Victor Chong,Jean-François Korobelnik,Peter K. Kaiser,Quan Dong Nguyen,Bernd Kirchhof,Allen C. Ho,Yuichiro Ogura,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Yuhwen Soo,Majid Anderesi,Georg Groetzbach,Bernd Sommerauer,Rupert Sandbrink,Rupert Sandbrink,Christian Simader,Ursula Schmidt-Erfurth +20 more
TL;DR: It is demonstrated that aflibercept is an effective treatment for AMD, with the every-2-month regimen offering the potential to reduce the risk from monthly intravitreal injections and the burden of monthly monitoring.
Journal ArticleDOI
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration: Ninety-Six–Week Results of the VIEW Studies
Ursula Schmidt-Erfurth,Peter K. Kaiser,Jean-François Korobelnik,David M. Brown,Victor Chong,Quan Dong Nguyen,Allen C. Ho,Yuichiro Ogura,Christian Simader,Glenn J. Jaffe,Jason S. Slakter,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Yuhwen Soo,Majid Anderesi,Olaf Sowade,Oliver Zeitz,Oliver Zeitz,Christiane Norenberg,Rupert Sandbrink,Rupert Sandbrink,Jeffrey S. Heier +23 more
TL;DR: All aflibercept and ranibizumab groups were equally effective in improving BCVA and preventing BCVA loss at 96 weeks, and the 2q8 a flibercept group was similar to ranibIZumab in visual acuity outcomes during 96 weeks, but with an average of 5 fewer injections.
Journal ArticleDOI
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.
David M. Brown,Peter A. Campochiaro,Robert B. Bhisitkul,Allen C. Ho,Sarah Gray,Namrata Saroj,Anthony P. Adamis,Roman G. Rubio,Wendy Yee Murahashi +8 more
TL;DR: Intraocular injections of ranibizumab provide an effective treatment for macular edema after central retinal vein occlusion, with low rates of ocular and nonocular safety events.
Journal ArticleDOI
Interim Results from the International Trial of Second Sight's Visual Prosthesis
Mark S. Humayun,Jessy D. Dorn,Lyndon da Cruz,Gislin Dagnelie,José-Alain Sahel,Paulo E. Stanga,Artur V. Cideciyan,Jacque L. Duncan,Dean Eliott,Eugene Filley,Allen C. Ho,Arturo Santos,Avinoam B. Safran,Aries Arditi,Lucian V. Del Priore,Lucian V. Del Priore,Robert J. Greenberg +16 more
TL;DR: The long-term safety results of Second Sight's retinal prosthesis system are acceptable, and most subjects with profound visual loss perform better on visual tasks with system than without it.
Journal ArticleDOI
Digital indocyanine green videoangiography of central serous chorioretinopathy
D. R. Guyer,Lawrence A. Yannuzzi,Jason S. Slakter,John A. Sorenson,Allen C. Ho,Dennis Orlock +5 more
TL;DR: The pathogenesis of CSC may be due to a choroidal vascular hyperpermeability with and without associated active pigment epithelial leaks and multiple presumed "occult" serous retinal pigment epithelium and neurosensory retina detachments.